CHELSEA ARNONE

Hospital Group Purchasing - Advocated in support of hospital group purchasing organizations and maintaining the GPO safe harbor. 340B Drug Pricing Program - Supported maintaining adequate reimbursement for hospitals purchasing prescription drugs through the 340B Drug Pricing Program. Advocated for preserving the current structure of the program and retaining the current prime vendor. Prescription Drug Pricing - Held Congressional briefing to highlight how hospitals are responding to high drug prices. Urged passage of legislation that would promote competition among prescription drug manufacturers: The CREATES Act (H.R. 965; S. 340); the FAST Generics Act (H.R. 985); the Biologic Patent Transparency Act (S.659); the Affordable Prescriptions for Patients Act (S. 1416); Surprise Billing - Monitored proposals to protect patients from receiving surprise medical bills. Urged inclusion of provisions that would provide for independent dispute resolution in legislation (H.R. 3630 -the No Surprises Act; S. 1895 - The Lower Health Care Costs Act).

Prescription Drug Pricing - Engaged to clarify provisions in the House (H.R. 3) and Senate (S. 2543) drug pricing bills. Supported passage of legislation that would promote competition among prescription drug manufacturers: The CREATES Act (H.R. 965; S. 340); the FAST Generics Act (H.R. 985); the Biologic Patent Transparency Act (S.659); the Affordable Prescriptions for Patients Act (S. 1416) Hospital Group Purchasing - Advocated in support of hospital group purchasing organizations and maintaining the GPO safe harbor. 340B Drug Pricing Program - Supported maintaining adequate reimbursement for hospitals purchasing prescription drugs through the 340B Drug Pricing Program. Advocated for preserving the current structure of the program and retaining the current prime vendor. Surprise Billing - Supported inclusion of provisions to provide for an independent dispute resolution process in legislation to address surprise bills (H.R. 3630; S. 1895). Health Care Costs - Monitored the development and release of the S. 1895, the Lower Health Care Costs Act. Overall Hospital Quality Star Ratings - Continued to urge improvements to methodology for overall hospital star rating system.

Hospital Group Purchasing - Advocated in support of hospital group purchasing organizations and maintaining the GPO safe harbor. Overall Hospital Quality Star Ratings System - Urged changes to the methodology of the Overall Hospital Quality Star Ratings System. 340B Drug Pricing Program - Supported maintaining adequate reimbursement for hospitals purchasing prescription drugs through the 340B Drug Pricing Program. Advocated for maintaining the current structure of the program and supported retaining the current prime vendor. Prescription Drug Pricing - Urged passage of legislation that would promote competition among prescription drug manufacturers. Supported passage of the CREATES Act (H.R. 965; S. 340). Supported passage of the FAST Generics Act (H.R. 985). Supported passage of Biologic Patent Transparency Act (S.659). Monitored ongoing Congressional discussions related modifying pharmacy benefit manager rebates and other legislation related to patents, pay-for-delay settlements and improvements to FDA resources regarding biosimilar medications. Medical Device and Hospital Cybersecurity - Monitored ongoing discussion around enhancing cybersecurity protections for medical devices and hospital networks. Supported additional resources to bolster efforts as well as regulatory flexibility that recognizes the complexity of preventing and responding to cyberattacks. Disaster Preparedness - Conducted education and outreach to describe hospital efforts and resources necessary to prepare for natural disasters and mass-casualty events.

Prescription Drug Pricing - Engaged to clarify provisions in the House (H.R. 3) and Senate (S. 2543) drug pricing bills. Supported passage of legislation that would promote competition among prescription drug manufacturers: The CREATES Act (H.R. 965; S. 340); the FAST Generics Act (H.R. 985); the Biologic Patent Transparency Act (S.659); the Affordable Prescriptions for Patients Act (S. 1416) Hospital Group Purchasing - Advocated in support of hospital group purchasing organizations and maintaining the GPO safe harbor. 340B Drug Pricing Program - Supported maintaining adequate reimbursement for hospitals purchasing prescription drugs through the 340B Drug Pricing Program. Advocated for preserving the current structure of the program and retaining the current prime vendor. Surprise Billing - Supported inclusion of provisions to provide for an independent dispute resolution process in legislation to address surprise bills (H.R. 3630; S. 1895). Health Care Costs - Monitored the development and release of the S. 1895, the Lower Health Care Costs Act. Overall Hospital Quality Star Ratings - Continued to urge improvements to methodology for overall hospital star rating system.

Hospital Group Purchasing - Advocated in support of hospital group purchasing organizations and maintaining the GPO safe harbor. 340B Drug Pricing Program - Supported maintaining adequate reimbursement for hospitals purchasing prescription drugs through the 340B Drug Pricing Program. Advocated for preserving the current structure of the program and retaining the current prime vendor. Prescription Drug Pricing - Held Congressional briefing to highlight how hospitals are responding to high drug prices. Urged passage of legislation that would promote competition among prescription drug manufacturers: The CREATES Act (H.R. 965; S. 340); the FAST Generics Act (H.R. 985); the Biologic Patent Transparency Act (S.659); the Affordable Prescriptions for Patients Act (S. 1416); Surprise Billing - Monitored proposals to protect patients from receiving surprise medical bills. Urged inclusion of provisions that would provide for independent dispute resolution in legislation (H.R. 3630 -the No Surprises Act; S. 1895 - The Lower Health Care Costs Act).

Hospital Group Purchasing - Advocated in support of hospital group purchasing organizations and maintaining the GPO safe harbor. 340B Drug Pricing Program - Supported maintaining adequate reimbursement for hospitals purchasing prescription drugs through the 340B Drug Pricing Program. Advocated for preserving the current structure of the program and retaining the current prime vendor. Prescription Drug Pricing - Held Congressional briefing to highlight how hospitals are responding to high drug prices. Urged passage of legislation that would promote competition among prescription drug manufacturers: The CREATES Act (H.R. 965; S. 340); the FAST Generics Act (H.R. 985); the Biologic Patent Transparency Act (S.659); the Affordable Prescriptions for Patients Act (S. 1416); Surprise Billing - Monitored proposals to protect patients from receiving surprise medical bills. Urged inclusion of provisions that would provide for independent dispute resolution in legislation (H.R. 3630 -the No Surprises Act; S. 1895 - The Lower Health Care Costs Act).

Prescription Drug Pricing - Engaged to clarify provisions in the House (H.R. 3) and Senate (S. 2543) drug pricing bills. Supported passage of legislation that would promote competition among prescription drug manufacturers: The CREATES Act (H.R. 965; S. 340); the FAST Generics Act (H.R. 985); the Biologic Patent Transparency Act (S.659); the Affordable Prescriptions for Patients Act (S. 1416) Hospital Group Purchasing - Advocated in support of hospital group purchasing organizations and maintaining the GPO safe harbor. 340B Drug Pricing Program - Supported maintaining adequate reimbursement for hospitals purchasing prescription drugs through the 340B Drug Pricing Program. Advocated for preserving the current structure of the program and retaining the current prime vendor. Surprise Billing - Supported inclusion of provisions to provide for an independent dispute resolution process in legislation to address surprise bills (H.R. 3630; S. 1895). Health Care Costs - Monitored the development and release of the S. 1895, the Lower Health Care Costs Act. Overall Hospital Quality Star Ratings - Continued to urge improvements to methodology for overall hospital star rating system.

Hospital Group Purchasing - Advocated in support of hospital group purchasing organizations and maintaining the GPO safe harbor. Overall Hospital Quality Star Ratings System - Urged changes to the methodology of the Overall Hospital Quality Star Ratings System. 340B Drug Pricing Program - Supported maintaining adequate reimbursement for hospitals purchasing prescription drugs through the 340B Drug Pricing Program. Advocated for maintaining the current structure of the program and supported retaining the current prime vendor. Prescription Drug Pricing - Urged passage of legislation that would promote competition among prescription drug manufacturers. Supported passage of the CREATES Act (H.R. 965; S. 340). Supported passage of the FAST Generics Act (H.R. 985). Supported passage of Biologic Patent Transparency Act (S.659). Monitored ongoing Congressional discussions related modifying pharmacy benefit manager rebates and other legislation related to patents, pay-for-delay settlements and improvements to FDA resources regarding biosimilar medications. Medical Device and Hospital Cybersecurity - Monitored ongoing discussion around enhancing cybersecurity protections for medical devices and hospital networks. Supported additional resources to bolster efforts as well as regulatory flexibility that recognizes the complexity of preventing and responding to cyberattacks. Disaster Preparedness - Conducted education and outreach to describe hospital efforts and resources necessary to prepare for natural disasters and mass-casualty events.

Hospital Group Purchasing - Advocated in support of hospital group purchasing organizations and maintaining the GPO safe harbor. 340B Drug Pricing Program - Supported maintaining adequate reimbursement for hospitals purchasing prescription drugs through the 340B Drug Pricing Program. Advocated for preserving the current structure of the program and retaining the current prime vendor. Prescription Drug Pricing - Held Congressional briefing to highlight how hospitals are responding to high drug prices. Urged passage of legislation that would promote competition among prescription drug manufacturers: The CREATES Act (H.R. 965; S. 340); the FAST Generics Act (H.R. 985); the Biologic Patent Transparency Act (S.659); the Affordable Prescriptions for Patients Act (S. 1416); Surprise Billing - Monitored proposals to protect patients from receiving surprise medical bills. Urged inclusion of provisions that would provide for independent dispute resolution in legislation (H.R. 3630 -the No Surprises Act; S. 1895 - The Lower Health Care Costs Act).

Prescription Drug Pricing - Engaged to clarify provisions in the House (H.R. 3) and Senate (S. 2543) drug pricing bills. Supported passage of legislation that would promote competition among prescription drug manufacturers: The CREATES Act (H.R. 965; S. 340); the FAST Generics Act (H.R. 985); the Biologic Patent Transparency Act (S.659); the Affordable Prescriptions for Patients Act (S. 1416) Hospital Group Purchasing - Advocated in support of hospital group purchasing organizations and maintaining the GPO safe harbor. 340B Drug Pricing Program - Supported maintaining adequate reimbursement for hospitals purchasing prescription drugs through the 340B Drug Pricing Program. Advocated for preserving the current structure of the program and retaining the current prime vendor. Surprise Billing - Supported inclusion of provisions to provide for an independent dispute resolution process in legislation to address surprise bills (H.R. 3630; S. 1895). Health Care Costs - Monitored the development and release of the S. 1895, the Lower Health Care Costs Act. Overall Hospital Quality Star Ratings - Continued to urge improvements to methodology for overall hospital star rating system.

Hospital Group Purchasing - Advocated in support of hospital group purchasing organizations and maintaining the GPO safe harbor. 340B Drug Pricing Program - Supported maintaining adequate reimbursement for hospitals purchasing prescription drugs through the 340B Drug Pricing Program. Advocated for preserving the current structure of the program and retaining the current prime vendor. Prescription Drug Pricing - Held Congressional briefing to highlight how hospitals are responding to high drug prices. Urged passage of legislation that would promote competition among prescription drug manufacturers: The CREATES Act (H.R. 965; S. 340); the FAST Generics Act (H.R. 985); the Biologic Patent Transparency Act (S.659); the Affordable Prescriptions for Patients Act (S. 1416); Surprise Billing - Monitored proposals to protect patients from receiving surprise medical bills. Urged inclusion of provisions that would provide for independent dispute resolution in legislation (H.R. 3630 -the No Surprises Act; S. 1895 - The Lower Health Care Costs Act).

Prescription Drug Pricing - Engaged to clarify provisions in the House (H.R. 3) and Senate (S. 2543) drug pricing bills. Supported passage of legislation that would promote competition among prescription drug manufacturers: The CREATES Act (H.R. 965; S. 340); the FAST Generics Act (H.R. 985); the Biologic Patent Transparency Act (S.659); the Affordable Prescriptions for Patients Act (S. 1416) Hospital Group Purchasing - Advocated in support of hospital group purchasing organizations and maintaining the GPO safe harbor. 340B Drug Pricing Program - Supported maintaining adequate reimbursement for hospitals purchasing prescription drugs through the 340B Drug Pricing Program. Advocated for preserving the current structure of the program and retaining the current prime vendor. Surprise Billing - Supported inclusion of provisions to provide for an independent dispute resolution process in legislation to address surprise bills (H.R. 3630; S. 1895). Health Care Costs - Monitored the development and release of the S. 1895, the Lower Health Care Costs Act. Overall Hospital Quality Star Ratings - Continued to urge improvements to methodology for overall hospital star rating system.

Prescription Drug Pricing - Engaged to clarify provisions in the House (H.R. 3) and Senate (S. 2543) drug pricing bills. Supported passage of legislation that would promote competition among prescription drug manufacturers: The CREATES Act (H.R. 965; S. 340); the FAST Generics Act (H.R. 985); the Biologic Patent Transparency Act (S.659); the Affordable Prescriptions for Patients Act (S. 1416) Hospital Group Purchasing - Advocated in support of hospital group purchasing organizations and maintaining the GPO safe harbor. 340B Drug Pricing Program - Supported maintaining adequate reimbursement for hospitals purchasing prescription drugs through the 340B Drug Pricing Program. Advocated for preserving the current structure of the program and retaining the current prime vendor. Surprise Billing - Supported inclusion of provisions to provide for an independent dispute resolution process in legislation to address surprise bills (H.R. 3630; S. 1895). Health Care Costs - Monitored the development and release of the S. 1895, the Lower Health Care Costs Act. Overall Hospital Quality Star Ratings - Continued to urge improvements to methodology for overall hospital star rating system.

Medicaid Disproportionate Share Hospital (DSH) Payments - Urged Congress to continue delay of implementation of Medicaid DSH payment cuts. ACE Kids Act (H.R. 1226, S.317) - Urged passage of ACE Kids Act to promote greater care coordination and expand Medicaid treatment options for medically complex pediatric patients. Site-neutral Payments - Opposed efforts to reduce payment rates for hospital outpatient departments. Advocated for Congress to reverse site-neutral payments cuts implemented by the Centers for Medicare and Medicaid Services in the 2019 Outpatient Prospective Payment System final rule. Resident Physician Shortage Reduction Act (S. 348) - Supported passage of the Resident Physician Shortage Reduction Act to support an increase in the number of Medicare-supported graduate medical education residents.

Hospital Group Purchasing - Advocated in support of hospital group purchasing organizations and maintaining the GPO safe harbor. 340B Drug Pricing Program - Supported maintaining adequate reimbursement for hospitals purchasing prescription drugs through the 340B Drug Pricing Program. Advocated for preserving the current structure of the program and retaining the current prime vendor. Prescription Drug Pricing - Held Congressional briefing to highlight how hospitals are responding to high drug prices. Urged passage of legislation that would promote competition among prescription drug manufacturers: The CREATES Act (H.R. 965; S. 340); the FAST Generics Act (H.R. 985); the Biologic Patent Transparency Act (S.659); the Affordable Prescriptions for Patients Act (S. 1416); Surprise Billing - Monitored proposals to protect patients from receiving surprise medical bills. Urged inclusion of provisions that would provide for independent dispute resolution in legislation (H.R. 3630 -the No Surprises Act; S. 1895 - The Lower Health Care Costs Act).

Hospital Group Purchasing - Advocated in support of hospital group purchasing organizations and maintaining the GPO safe harbor. Overall Hospital Quality Star Ratings System - Urged changes to the methodology of the Overall Hospital Quality Star Ratings System. 340B Drug Pricing Program - Supported maintaining adequate reimbursement for hospitals purchasing prescription drugs through the 340B Drug Pricing Program. Advocated for maintaining the current structure of the program and supported retaining the current prime vendor. Prescription Drug Pricing - Urged passage of legislation that would promote competition among prescription drug manufacturers. Supported passage of the CREATES Act (H.R. 965; S. 340). Supported passage of the FAST Generics Act (H.R. 985). Supported passage of Biologic Patent Transparency Act (S.659). Monitored ongoing Congressional discussions related modifying pharmacy benefit manager rebates and other legislation related to patents, pay-for-delay settlements and improvements to FDA resources regarding biosimilar medications. Medical Device and Hospital Cybersecurity - Monitored ongoing discussion around enhancing cybersecurity protections for medical devices and hospital networks. Supported additional resources to bolster efforts as well as regulatory flexibility that recognizes the complexity of preventing and responding to cyberattacks. Disaster Preparedness - Conducted education and outreach to describe hospital efforts and resources necessary to prepare for natural disasters and mass-casualty events.

Prescription Drug Pricing - Engaged to clarify provisions in the House (H.R. 3) and Senate (S. 2543) drug pricing bills. Supported passage of legislation that would promote competition among prescription drug manufacturers: The CREATES Act (H.R. 965; S. 340); the FAST Generics Act (H.R. 985); the Biologic Patent Transparency Act (S.659); the Affordable Prescriptions for Patients Act (S. 1416) Hospital Group Purchasing - Advocated in support of hospital group purchasing organizations and maintaining the GPO safe harbor. 340B Drug Pricing Program - Supported maintaining adequate reimbursement for hospitals purchasing prescription drugs through the 340B Drug Pricing Program. Advocated for preserving the current structure of the program and retaining the current prime vendor. Surprise Billing - Supported inclusion of provisions to provide for an independent dispute resolution process in legislation to address surprise bills (H.R. 3630; S. 1895). Health Care Costs - Monitored the development and release of the S. 1895, the Lower Health Care Costs Act. Overall Hospital Quality Star Ratings - Continued to urge improvements to methodology for overall hospital star rating system.

Medicaid Disproportionate Share Hospital (DSH) Payments - Urged Congress to continue delay of implementation of Medicaid DSH payment cuts. ACE Kids Act (H.R. 1226, S.317) - Urged passage of ACE Kids Act to promote greater care coordination and expand Medicaid treatment options for medically complex pediatric patients. Site-neutral Payments - Opposed efforts to reduce payment rates for hospital outpatient departments. Advocated for Congress to reverse site-neutral payments cuts implemented by the Centers for Medicare and Medicaid Services in the 2019 Outpatient Prospective Payment System final rule. Resident Physician Shortage Reduction Act (S. 348) - Supported passage of the Resident Physician Shortage Reduction Act to support an increase in the number of Medicare-supported graduate medical education residents.

Medicaid Disproportionate Share Hospital (DSH) Payments - Urged Congress to approve legislation to delay implementation of Medicaid DSH payment cuts. Site-neutral Payments - Supported passage of the PLACE Act (H.R. 2552) which would reverse site-neutral payments cuts implemented by the Centers for Medicare and Medicaid Services. Resident Physician Shortage Reduction Act (S. 348) - Supported passage of the Resident Physician Shortage Reduction Act to support an increase in the number of Medicare-supported graduate medical education residents.

Medicaid Disproportionate Share Hospital (DSH) Payments - Urged Congress to approve legislation to delay implementation of Medicaid DSH payment cuts. Site-neutral Payments - Supported passage of the PLACE Act (H.R. 2552) which would reverse site-neutral payments cuts implemented by the Centers for Medicare and Medicaid Services. Resident Physician Shortage Reduction Act (S. 348) - Supported passage of the Resident Physician Shortage Reduction Act to support an increase in the number of Medicare-supported graduate medical education residents. Home Infusion Therapy Reimbursement - Opposed CMS's implementation of unnecessary payment restrictions around Medicare's home infusion benefit. Urged Congress to act to expand access to home infusion therapy.

Hospital Group Purchasing - Advocated in support of hospital group purchasing organizations and maintaining the GPO safe harbor. Overall Hospital Quality Star Ratings System - Urged changes to the methodology of the Overall Hospital Quality Star Ratings System. 340B Drug Pricing Program - Supported maintaining adequate reimbursement for hospitals purchasing prescription drugs through the 340B Drug Pricing Program. Advocated for maintaining the current structure of the program and supported retaining the current prime vendor. Prescription Drug Pricing - Urged passage of legislation that would promote competition among prescription drug manufacturers. Supported passage of the CREATES Act (H.R. 965; S. 340). Supported passage of the FAST Generics Act (H.R. 985). Supported passage of Biologic Patent Transparency Act (S.659). Monitored ongoing Congressional discussions related modifying pharmacy benefit manager rebates and other legislation related to patents, pay-for-delay settlements and improvements to FDA resources regarding biosimilar medications. Medical Device and Hospital Cybersecurity - Monitored ongoing discussion around enhancing cybersecurity protections for medical devices and hospital networks. Supported additional resources to bolster efforts as well as regulatory flexibility that recognizes the complexity of preventing and responding to cyberattacks. Disaster Preparedness - Conducted education and outreach to describe hospital efforts and resources necessary to prepare for natural disasters and mass-casualty events.

Hospital Group Purchasing - Advocated in support of hospital group purchasing organizations and maintaining the GPO safe harbor. 340B Drug Pricing Program - Supported maintaining adequate reimbursement for hospitals purchasing prescription drugs through the 340B Drug Pricing Program. Advocated for preserving the current structure of the program and retaining the current prime vendor. Prescription Drug Pricing - Held Congressional briefing to highlight how hospitals are responding to high drug prices. Urged passage of legislation that would promote competition among prescription drug manufacturers: The CREATES Act (H.R. 965; S. 340); the FAST Generics Act (H.R. 985); the Biologic Patent Transparency Act (S.659); the Affordable Prescriptions for Patients Act (S. 1416); Surprise Billing - Monitored proposals to protect patients from receiving surprise medical bills. Urged inclusion of provisions that would provide for independent dispute resolution in legislation (H.R. 3630 -the No Surprises Act; S. 1895 - The Lower Health Care Costs Act).

Prescription Drug Pricing - Engaged to clarify provisions in the House (H.R. 3) and Senate (S. 2543) drug pricing bills. Supported passage of legislation that would promote competition among prescription drug manufacturers: The CREATES Act (H.R. 965; S. 340); the FAST Generics Act (H.R. 985); the Biologic Patent Transparency Act (S.659); the Affordable Prescriptions for Patients Act (S. 1416) Hospital Group Purchasing - Advocated in support of hospital group purchasing organizations and maintaining the GPO safe harbor. 340B Drug Pricing Program - Supported maintaining adequate reimbursement for hospitals purchasing prescription drugs through the 340B Drug Pricing Program. Advocated for preserving the current structure of the program and retaining the current prime vendor. Surprise Billing - Supported inclusion of provisions to provide for an independent dispute resolution process in legislation to address surprise bills (H.R. 3630; S. 1895). Health Care Costs - Monitored the development and release of the S. 1895, the Lower Health Care Costs Act. Overall Hospital Quality Star Ratings - Continued to urge improvements to methodology for overall hospital star rating system.

340B Drug Discount Program - Opposed Medicare reimbursement reductions for hospitals eligible for the 340B drug discount program. Supported passage of H.R. 4392. Opposed H.R. 4710, S. 2312 and S.2453 and monitored congressional discussions around the program. Medicare Extenders - Supported extension of Medicare programs that support low-volume and Medicare-dependent hospitals included in H.R.1892. Medicaid Disproportionate Share Hospital (DSH) Payments - Supported delay of implementation of Medicaid DSH payment cuts included in H.R. 1892. Children's Hospital GME Support Reauthorization Act (H.R.5385, S.2597) - Endorsed passage of legislation to reauthorize the Children's Hospital GME program. Supported change to home infusion payments for Part B DME infusion drugs and infusion services payments included in H.R. 1892.

Group Purchasing - Conducted education and outreach efforts about the value hospital group purchasing organizations deliver the U.S. health care system. Drug Pricing - Supported the CREATES Act (S. 974), The Fair Access to Safe and Timely Generics Act (H.R. 2051), The Preserving Access to Affordable Generics (S.124), The Increasing Competition in Pharmaceuticals Act (S.297) and The Lower Drug Costs through Competition Act (H.R. 749). 340B Drug Discount program - Supported passage of H.R. 4392. Opposed H.R. 4710, S. 2312 and S.2453 and monitored ongoing congressional reports and discussions around the program. Children's Health Insurance Program - Supported passage of legislation to extend the Children's Health Insurance Program. Supported provision in H.R. 195 to extend the program for 6 years, and provisions in H.R. 1892 that continued funding for four additional years. Supported efforts to stabilize ACA insurance markets - including continuing funding for cost-sharing reduction subsidies and other efforts to stabilize insurance markets. Supported inclusion of provision to repeal the Independent Payment Advisory Board (IPAB) in H.R. 1892. Opioid Abuse - Monitored legislation to enhance funding and treatment options to address opioid abuse and addiction issues. Engaged in support of taking steps to ease shortages of hospital-administered intravenous opioid solutions.

Group Purchasing - Conducted education and outreach efforts about the value hospital group purchasing organizations deliver the U.S. health care system. Drug Pricing - Supported the CREATES Act (S. 974), The Fair Access to Safe and Timely Generics Act (H.R. 2051), The Preserving Access to Affordable Generics (S.124), The Increasing Competition in Pharmaceuticals Act (S.297) and The Lower Drug Costs through Competition Act (H.R. 749). 340B Drug Discount program - Supported passage of H.R. 4392. Opposed H.R. 4710, S. 2312 and S.2453 and monitored ongoing congressional reports and discussions around the program. Children's Health Insurance Program - Supported passage of legislation to extend the Children's Health Insurance Program. Supported provision in H.R. 195 to extend the program for 6 years, and provisions in H.R. 1892 that continued funding for four additional years. Supported efforts to stabilize ACA insurance markets - including continuing funding for cost-sharing reduction subsidies and other efforts to stabilize insurance markets. Supported inclusion of provision to repeal the Independent Payment Advisory Board (IPAB) in H.R. 1892. Opioid Abuse - Monitored legislation to enhance funding and treatment options to address opioid abuse and addiction issues. Engaged in support of taking steps to ease shortages of hospital-administered intravenous opioid solutions.

Monitored provisions in H.R. 195 to repeal or delay tax provisions included in the Affordable Care Act including the medical device tax, tax assessment on health insurance plans and high-value "Cadillac" insurance plans. Hospital Tax Exemption and Community Benefit - Monitored congressional activities for potential changes to hospital community benefit requirements to maintain tax exemption.

Group Purchasing - Conducted education and outreach efforts about the value hospital group purchasing organizations deliver the U.S. health care system. Drug Pricing - Supported the CREATES Act (S. 974), The Fair Access to Safe and Timely Generics Act (H.R. 2051), The Preserving Access to Affordable Generics (S.124), The Increasing Competition in Pharmaceuticals Act (S.297) and The Lower Drug Costs through Competition Act (H.R. 749). 340B Drug Discount program - Supported passage of H.R. 4392. Opposed H.R. 4710, S. 2312 and S.2453 and monitored ongoing congressional reports and discussions around the program. Children's Health Insurance Program - Supported passage of legislation to extend the Children's Health Insurance Program. Supported provision in H.R. 195 to extend the program for 6 years, and provisions in H.R. 1892 that continued funding for four additional years. Supported efforts to stabilize ACA insurance markets - including continuing funding for cost-sharing reduction subsidies and other efforts to stabilize insurance markets. Supported inclusion of provision to repeal the Independent Payment Advisory Board (IPAB) in H.R. 1892. Opioid Abuse - Monitored legislation to enhance funding and treatment options to address opioid abuse and addiction issues. Engaged in support of taking steps to ease shortages of hospital-administered intravenous opioid solutions.

340B Drug Pricing Program - Highlighted importance of the 340B Drug Pricing program for safety net hospitals and monitored ongoing discussions around reforming the program. Supported passage of H.R. 4392, H.R 6071. Opposed H.R. 4710, H.R. 6240, S. 2312 and S.2453. Group Purchasing - Conducted education and outreach efforts about the value hospital group purchasing organizations deliver the U.S. health care system. Drug Shortages - Advocated for Drug Enforcement Agency to modify total production quotas for injectable opioid solutions to address hospital shortages. Drug Pricing - Supported the CREATES Act (S. 974), The Fair Access to Safe and Timely Generics Act (H.R. 2051), The Preserving Access to Affordable Generics (S.124), The Increasing Competition in Pharmaceuticals Act (S.297) and The Lower Drug Costs through Competition Act (H.R. 749). Opioid Abuse - Supported House passage of H.R. 6 and ongoing efforts to enhance funding and treatment options to address opioid abuse and addiction issues. Overall Hospital Quality Star Ratings - Urged modifications to the methodology used to calculate Overall Hospital Quality Star Ratings Program. Prescription Drug Compounding - Supported ongoing efforts to maintain access to safe and effective drug compounding as the Drug Quality and Safety Act is implemented. Stark Law Reform - Monitored discussions in the House and Senate seeking reforms to the Stark Law. Voiced support for reforms that ease barriers to value-based care arrangements. Medical Device Cybersecurity - Urged additional steps to promote enhanced cybersecurity for networked medical devices.

Group Purchasing - Conducted education and outreach efforts about the value hospital group purchasing organizations deliver the U.S. health care system. 340B Drug Pricing Program - Opposed changes to eligibility and the structure of the 340B Drug Pricing Program. Supported passage of H.R. 4392 and H.R 6071. Opposed H.R. 4710, H.R. 6240, S. 2312 and S.2453. Drug Shortages - Engaged in discussions around how ongoing shortages of prescription drugs are impacting hospitals and possible solutions. Advocated for the Drug Enforcement Agency to modify total annual production quotas to address hospital shortage of injectable opioid solutions. Drug Pricing - Supported the CREATES Act (S. 974), The Fair Access to Safe and Timely Generics Act (H.R. 2051), The Preserving Access to Affordable Generics (S.124), The Increasing Competition in Pharmaceuticals Act (S.297) and The Lower Drug Costs through Competition Act (H.R. 749). Biosimilar Drug adoption - Supported administrative proposals that would expand the adoption of biosimilar medications. Urged the Food and Drug Administration to finalize guidance related biosimilar interchangeability. Opioid Abuse - Supported changes to privacy requirements under 42 CFR Part 2 to better support coordinated care for patients. Supported H.R. 6082. Children's Hospital GME Support Reauthorization Act (H.R.5385, S.2597) - Endorsed passage of legislation to reauthorize the Children's Hospital GME program. Overall Hospital Quality Star Ratings - Urged modifications to the methodology used to calculate Overall Hospital Quality Star Ratings Program. Stark Law Reform - Monitored discussions in the House and Senate seeking reforms to the Stark Law. Voiced support for reforms that ease barriers to value-based care arrangements.

340B Drug Pricing Program - Opposed changes to eligibility and the structure of the 340B Drug Pricing Program. Supported passage of H.R. 4392, H.R 6071. Opposed H.R. 4710, H.R. 6240, S. 2312 and S.2453. Group Purchasing - Conducted education and outreach efforts about the value hospital group purchasing organizations deliver the U.S. health care system. Drug Shortages - Advocated for Drug Enforcement Agency to modify total production quotas for injectable opioid solutions to address hospital shortages. Drug Pricing - Supported the CREATES Act (S. 974), The Fair Access to Safe and Timely Generics Act (H.R. 2051), The Preserving Access to Affordable Generics (S.124), The Increasing Competition in Pharmaceuticals Act (S.297) and The Lower Drug Costs through Competition Act (H.R. 749). Biosimilar Drug adoption - Supported administrative proposals that would expand the adoption of biosimilar medications. Urged the Food and Drug Administration to finalize guidance related biosimilar interchangeability. Opioid Abuse - Supported passage of H.R. 6 and ongoing efforts to enhance funding and treatment options to address opioid abuse and addiction issues. Supported changes to privacy requirements under 42 CFR Part 2 to better support coordinated care for patients. Overall Hospital Quality Star Ratings - Urged modifications to the methodology used to calculate Overall Hospital Quality Star Ratings Program. Prescription Drug Compounding - Supported ongoing efforts to maintain access to safe and effective drug compounding as the Drug Quality and Safety Act is implemented. Stark Law Reform - Monitored discussions in the House and Senate seeking reforms to the Stark Law. Voiced support for reforms that ease barriers to value-based care arrangements.

340B Drug Discount Program - Opposed Medicare reimbursement reductions for hospitals eligible for the 340B drug discount program. Supported passage of H.R. 4392. Opposed H.R. 4710, S. 2312 and S.2453 and monitored congressional discussions around the program. Medicare Extenders - Supported extension of Medicare programs that support low-volume and Medicare-dependent hospitals included in H.R.1892. Medicaid Disproportionate Share Hospital (DSH) Payments - Supported delay of implementation of Medicaid DSH payment cuts included in H.R. 1892. Children's Hospital GME Support Reauthorization Act (H.R.5385, S.2597) - Endorsed passage of legislation to reauthorize the Children's Hospital GME program. Supported change to home infusion payments for Part B DME infusion drugs and infusion services payments included in H.R. 1892.

340B Drug Pricing Program - Opposed Medicare reimbursement reductions for hospitals eligible for the 340B drug pricing program. Supported passage of H.R. 4392, H.R 6071. Opposed H.R. 4710, H.R. 6240, S. 2312 and S.2453. Outpatient Prospective Payment System Site-Neutral Payment Reductions - Opposed implementation of Medicare payment changes that would reduce reimbursement for hospital outpatient facilities.

Group Purchasing - Conducted education and outreach efforts about the value hospital group purchasing organizations deliver the U.S. health care system. 340B Drug Pricing Program - Opposed changes to eligibility and the structure of the 340B Drug Pricing Program. Supported passage of H.R. 4392 and H.R 6071. Opposed H.R. 4710, H.R. 6240, S. 2312 and S.2453. Drug Shortages - Engaged in discussions around how ongoing shortages of prescription drugs are impacting hospitals and possible solutions. Advocated for the Drug Enforcement Agency to modify total annual production quotas to address hospital shortage of injectable opioid solutions. Drug Pricing - Supported the CREATES Act (S. 974), The Fair Access to Safe and Timely Generics Act (H.R. 2051), The Preserving Access to Affordable Generics (S.124), The Increasing Competition in Pharmaceuticals Act (S.297) and The Lower Drug Costs through Competition Act (H.R. 749). Biosimilar Drug adoption - Supported administrative proposals that would expand the adoption of biosimilar medications. Urged the Food and Drug Administration to finalize guidance related biosimilar interchangeability. Opioid Abuse - Supported changes to privacy requirements under 42 CFR Part 2 to better support coordinated care for patients. Supported H.R. 6082. Children's Hospital GME Support Reauthorization Act (H.R.5385, S.2597) - Endorsed passage of legislation to reauthorize the Children's Hospital GME program. Overall Hospital Quality Star Ratings - Urged modifications to the methodology used to calculate Overall Hospital Quality Star Ratings Program. Stark Law Reform - Monitored discussions in the House and Senate seeking reforms to the Stark Law. Voiced support for reforms that ease barriers to value-based care arrangements.

340B Drug Pricing Program - Opposed changes to eligibility and the structure of the 340B Drug Pricing Program. Supported passage of H.R. 4392, H.R 6071. Opposed H.R. 4710, H.R. 6240, S. 2312 and S.2453. Group Purchasing - Conducted education and outreach efforts about the value hospital group purchasing organizations deliver the U.S. health care system. Drug Shortages - Advocated for Drug Enforcement Agency to modify total production quotas for injectable opioid solutions to address hospital shortages. Drug Pricing - Supported the CREATES Act (S. 974), The Fair Access to Safe and Timely Generics Act (H.R. 2051), The Preserving Access to Affordable Generics (S.124), The Increasing Competition in Pharmaceuticals Act (S.297) and The Lower Drug Costs through Competition Act (H.R. 749). Biosimilar Drug adoption - Supported administrative proposals that would expand the adoption of biosimilar medications. Urged the Food and Drug Administration to finalize guidance related biosimilar interchangeability. Opioid Abuse - Supported passage of H.R. 6 and ongoing efforts to enhance funding and treatment options to address opioid abuse and addiction issues. Supported changes to privacy requirements under 42 CFR Part 2 to better support coordinated care for patients. Overall Hospital Quality Star Ratings - Urged modifications to the methodology used to calculate Overall Hospital Quality Star Ratings Program. Prescription Drug Compounding - Supported ongoing efforts to maintain access to safe and effective drug compounding as the Drug Quality and Safety Act is implemented. Stark Law Reform - Monitored discussions in the House and Senate seeking reforms to the Stark Law. Voiced support for reforms that ease barriers to value-based care arrangements.

Group Purchasing - Conducted education and outreach efforts about the value hospital group purchasing organizations deliver the U.S. health care system. Drug Pricing - Supported the CREATES Act (S. 974), The Fair Access to Safe and Timely Generics Act (H.R. 2051), The Preserving Access to Affordable Generics (S.124), The Increasing Competition in Pharmaceuticals Act (S.297) and The Lower Drug Costs through Competition Act (H.R. 749). 340B Drug Discount program - Supported passage of H.R. 4392. Opposed H.R. 4710, S. 2312 and S.2453 and monitored ongoing congressional reports and discussions around the program. Children's Health Insurance Program - Supported passage of legislation to extend the Children's Health Insurance Program. Supported provision in H.R. 195 to extend the program for 6 years, and provisions in H.R. 1892 that continued funding for four additional years. Supported efforts to stabilize ACA insurance markets - including continuing funding for cost-sharing reduction subsidies and other efforts to stabilize insurance markets. Supported inclusion of provision to repeal the Independent Payment Advisory Board (IPAB) in H.R. 1892. Opioid Abuse - Monitored legislation to enhance funding and treatment options to address opioid abuse and addiction issues. Engaged in support of taking steps to ease shortages of hospital-administered intravenous opioid solutions.

340B Drug Pricing Program - Highlighted importance of the 340B Drug Pricing program for safety net hospitals and monitored ongoing discussions around reforming the program. Supported passage of H.R. 4392, H.R 6071. Opposed H.R. 4710, H.R. 6240, S. 2312 and S.2453. Group Purchasing - Conducted education and outreach efforts about the value hospital group purchasing organizations deliver the U.S. health care system. Drug Shortages - Advocated for Drug Enforcement Agency to modify total production quotas for injectable opioid solutions to address hospital shortages. Drug Pricing - Supported the CREATES Act (S. 974), The Fair Access to Safe and Timely Generics Act (H.R. 2051), The Preserving Access to Affordable Generics (S.124), The Increasing Competition in Pharmaceuticals Act (S.297) and The Lower Drug Costs through Competition Act (H.R. 749). Opioid Abuse - Supported House passage of H.R. 6 and ongoing efforts to enhance funding and treatment options to address opioid abuse and addiction issues. Overall Hospital Quality Star Ratings - Urged modifications to the methodology used to calculate Overall Hospital Quality Star Ratings Program. Prescription Drug Compounding - Supported ongoing efforts to maintain access to safe and effective drug compounding as the Drug Quality and Safety Act is implemented. Stark Law Reform - Monitored discussions in the House and Senate seeking reforms to the Stark Law. Voiced support for reforms that ease barriers to value-based care arrangements. Medical Device Cybersecurity - Urged additional steps to promote enhanced cybersecurity for networked medical devices.

340B Drug Pricing Program - Raised opposition to Medicare reimbursement reductions for hospitals eligible for the 340B drug pricing program. Supported passage of H.R. 4392, H.R 6071. Opposed H.R. 4710, H.R. 6240, S. 2312 and S.2453. Supported Limited Repeal of the IMD Exclusion for substance abuse disorder that was included in H.R. 6, the SUPPORT Communities Act. Children's Hospital GME Support Reauthorization Act (H.R.5385, S.2597) - Endorsed passage of legislation to reauthorize the Children's Hospital GME program.

340B Drug Pricing Program - Opposed Medicare reimbursement reductions for hospitals eligible for the 340B drug pricing program. Supported passage of H.R. 4392, H.R 6071. Opposed H.R. 4710, H.R. 6240, S. 2312 and S.2453. Supported partial relaxation of the IMD Exclusion for substance abuse disorder included in H.R. 6, the SUPPORT Communities Act. Children's Hospital GME Support Reauthorization Act (H.R.5385, S.2597) - Endorsed passage of legislation to reauthorize the Children's Hospital GME program. Supported implementation of a competitive acquisition program for prescription drugs under Medicare Part B.

340B Drug Pricing Program - Raised opposition to Medicare reimbursement reductions for hospitals eligible for the 340B drug pricing program. Supported passage of H.R. 4392, H.R 6071. Opposed H.R. 4710, H.R. 6240, S. 2312 and S.2453. Supported Limited Repeal of the IMD Exclusion for substance abuse disorder that was included in H.R. 6, the SUPPORT Communities Act. Children's Hospital GME Support Reauthorization Act (H.R.5385, S.2597) - Endorsed passage of legislation to reauthorize the Children's Hospital GME program.

340B Drug Pricing Program - Opposed Medicare reimbursement reductions for hospitals eligible for the 340B drug pricing program. Supported passage of H.R. 4392, H.R 6071. Opposed H.R. 4710, H.R. 6240, S. 2312 and S.2453. Supported partial relaxation of the IMD Exclusion for substance abuse disorder included in H.R. 6, the SUPPORT Communities Act. Children's Hospital GME Support Reauthorization Act (H.R.5385, S.2597) - Endorsed passage of legislation to reauthorize the Children's Hospital GME program. Supported implementation of a competitive acquisition program for prescription drugs under Medicare Part B.

340B Drug Pricing Program - Opposed Medicare reimbursement reductions for hospitals eligible for the 340B drug pricing program. Supported passage of H.R. 4392, H.R 6071. Opposed H.R. 4710, H.R. 6240, S. 2312 and S.2453. Outpatient Prospective Payment System Site-Neutral Payment Reductions - Opposed implementation of Medicare payment changes that would reduce reimbursement for hospital outpatient facilities.

Group Purchasing - Conducted education and outreach efforts about the value hospital group purchasing organizations deliver the U.S. health care system. 340B Drug Pricing Program - Opposed changes to eligibility and the structure of the 340B Drug Pricing Program. Supported passage of H.R. 4392 and H.R 6071. Opposed H.R. 4710, H.R. 6240, S. 2312 and S.2453. Drug Shortages - Engaged in discussions around how ongoing shortages of prescription drugs are impacting hospitals and possible solutions. Advocated for the Drug Enforcement Agency to modify total annual production quotas to address hospital shortage of injectable opioid solutions. Drug Pricing - Supported the CREATES Act (S. 974), The Fair Access to Safe and Timely Generics Act (H.R. 2051), The Preserving Access to Affordable Generics (S.124), The Increasing Competition in Pharmaceuticals Act (S.297) and The Lower Drug Costs through Competition Act (H.R. 749). Biosimilar Drug adoption - Supported administrative proposals that would expand the adoption of biosimilar medications. Urged the Food and Drug Administration to finalize guidance related biosimilar interchangeability. Opioid Abuse - Supported changes to privacy requirements under 42 CFR Part 2 to better support coordinated care for patients. Supported H.R. 6082. Children's Hospital GME Support Reauthorization Act (H.R.5385, S.2597) - Endorsed passage of legislation to reauthorize the Children's Hospital GME program. Overall Hospital Quality Star Ratings - Urged modifications to the methodology used to calculate Overall Hospital Quality Star Ratings Program. Stark Law Reform - Monitored discussions in the House and Senate seeking reforms to the Stark Law. Voiced support for reforms that ease barriers to value-based care arrangements.

340B Drug Pricing Program - Opposed changes to eligibility and the structure of the 340B Drug Pricing Program. Supported passage of H.R. 4392, H.R 6071. Opposed H.R. 4710, H.R. 6240, S. 2312 and S.2453. Group Purchasing - Conducted education and outreach efforts about the value hospital group purchasing organizations deliver the U.S. health care system. Drug Shortages - Advocated for Drug Enforcement Agency to modify total production quotas for injectable opioid solutions to address hospital shortages. Drug Pricing - Supported the CREATES Act (S. 974), The Fair Access to Safe and Timely Generics Act (H.R. 2051), The Preserving Access to Affordable Generics (S.124), The Increasing Competition in Pharmaceuticals Act (S.297) and The Lower Drug Costs through Competition Act (H.R. 749). Biosimilar Drug adoption - Supported administrative proposals that would expand the adoption of biosimilar medications. Urged the Food and Drug Administration to finalize guidance related biosimilar interchangeability. Opioid Abuse - Supported passage of H.R. 6 and ongoing efforts to enhance funding and treatment options to address opioid abuse and addiction issues. Supported changes to privacy requirements under 42 CFR Part 2 to better support coordinated care for patients. Overall Hospital Quality Star Ratings - Urged modifications to the methodology used to calculate Overall Hospital Quality Star Ratings Program. Prescription Drug Compounding - Supported ongoing efforts to maintain access to safe and effective drug compounding as the Drug Quality and Safety Act is implemented. Stark Law Reform - Monitored discussions in the House and Senate seeking reforms to the Stark Law. Voiced support for reforms that ease barriers to value-based care arrangements.

Group Purchasing - Conducted education and outreach efforts about the value hospital group purchasing organizations deliver the U.S. health care system. Drug Pricing - Supported the CREATES Act (S. 974), The Fair Access to Safe and Timely Generics Act (H.R. 2051), The Preserving Access to Affordable Generics (S.124), The Increasing Competition in Pharmaceuticals Act (S.297) and The Lower Drug Costs through Competition Act (H.R. 749). 340B Drug Discount program - Supported passage of H.R. 4392. Opposed H.R. 4710, S. 2312 and S.2453 and monitored ongoing congressional reports and discussions around the program. Children's Health Insurance Program - Supported passage of legislation to extend the Children's Health Insurance Program. Supported provision in H.R. 195 to extend the program for 6 years, and provisions in H.R. 1892 that continued funding for four additional years. Supported efforts to stabilize ACA insurance markets - including continuing funding for cost-sharing reduction subsidies and other efforts to stabilize insurance markets. Supported inclusion of provision to repeal the Independent Payment Advisory Board (IPAB) in H.R. 1892. Opioid Abuse - Monitored legislation to enhance funding and treatment options to address opioid abuse and addiction issues. Engaged in support of taking steps to ease shortages of hospital-administered intravenous opioid solutions.

340B Drug Pricing Program - Highlighted importance of the 340B Drug Pricing program for safety net hospitals and monitored ongoing discussions around reforming the program. Supported passage of H.R. 4392, H.R 6071. Opposed H.R. 4710, H.R. 6240, S. 2312 and S.2453. Group Purchasing - Conducted education and outreach efforts about the value hospital group purchasing organizations deliver the U.S. health care system. Drug Shortages - Advocated for Drug Enforcement Agency to modify total production quotas for injectable opioid solutions to address hospital shortages. Drug Pricing - Supported the CREATES Act (S. 974), The Fair Access to Safe and Timely Generics Act (H.R. 2051), The Preserving Access to Affordable Generics (S.124), The Increasing Competition in Pharmaceuticals Act (S.297) and The Lower Drug Costs through Competition Act (H.R. 749). Opioid Abuse - Supported House passage of H.R. 6 and ongoing efforts to enhance funding and treatment options to address opioid abuse and addiction issues. Overall Hospital Quality Star Ratings - Urged modifications to the methodology used to calculate Overall Hospital Quality Star Ratings Program. Prescription Drug Compounding - Supported ongoing efforts to maintain access to safe and effective drug compounding as the Drug Quality and Safety Act is implemented. Stark Law Reform - Monitored discussions in the House and Senate seeking reforms to the Stark Law. Voiced support for reforms that ease barriers to value-based care arrangements. Medical Device Cybersecurity - Urged additional steps to promote enhanced cybersecurity for networked medical devices.

340B Drug Discount Program - Opposed Medicare reimbursement reductions for hospitals eligible for the 340B drug discount program. Supported passage of H.R. 4392. Opposed H.R. 4710, S. 2312 and S.2453 and monitored congressional discussions around the program. Medicare Extenders - Supported extension of Medicare programs that support low-volume and Medicare-dependent hospitals included in H.R.1892. Medicaid Disproportionate Share Hospital (DSH) Payments - Supported delay of implementation of Medicaid DSH payment cuts included in H.R. 1892. Children's Hospital GME Support Reauthorization Act (H.R.5385, S.2597) - Endorsed passage of legislation to reauthorize the Children's Hospital GME program. Supported change to home infusion payments for Part B DME infusion drugs and infusion services payments included in H.R. 1892.

340B Drug Pricing Program - Opposed Medicare reimbursement reductions for hospitals eligible for the 340B drug pricing program. Supported passage of H.R. 4392, H.R 6071. Opposed H.R. 4710, H.R. 6240, S. 2312 and S.2453. Supported partial relaxation of the IMD Exclusion for substance abuse disorder included in H.R. 6, the SUPPORT Communities Act. Children's Hospital GME Support Reauthorization Act (H.R.5385, S.2597) - Endorsed passage of legislation to reauthorize the Children's Hospital GME program. Supported implementation of a competitive acquisition program for prescription drugs under Medicare Part B.

Group Purchasing - Conducted education and outreach efforts about the value hospital group purchasing organizations deliver the U.S. health care system. 340B Drug Pricing Program - Opposed changes to eligibility and the structure of the 340B Drug Pricing Program. Supported passage of H.R. 4392 and H.R 6071. Opposed H.R. 4710, H.R. 6240, S. 2312 and S.2453. Drug Shortages - Engaged in discussions around how ongoing shortages of prescription drugs are impacting hospitals and possible solutions. Advocated for the Drug Enforcement Agency to modify total annual production quotas to address hospital shortage of injectable opioid solutions. Drug Pricing - Supported the CREATES Act (S. 974), The Fair Access to Safe and Timely Generics Act (H.R. 2051), The Preserving Access to Affordable Generics (S.124), The Increasing Competition in Pharmaceuticals Act (S.297) and The Lower Drug Costs through Competition Act (H.R. 749). Biosimilar Drug adoption - Supported administrative proposals that would expand the adoption of biosimilar medications. Urged the Food and Drug Administration to finalize guidance related biosimilar interchangeability. Opioid Abuse - Supported changes to privacy requirements under 42 CFR Part 2 to better support coordinated care for patients. Supported H.R. 6082. Children's Hospital GME Support Reauthorization Act (H.R.5385, S.2597) - Endorsed passage of legislation to reauthorize the Children's Hospital GME program. Overall Hospital Quality Star Ratings - Urged modifications to the methodology used to calculate Overall Hospital Quality Star Ratings Program. Stark Law Reform - Monitored discussions in the House and Senate seeking reforms to the Stark Law. Voiced support for reforms that ease barriers to value-based care arrangements.

340B Drug Discount Program - Opposed Medicare reimbursement reductions for hospitals eligible for the 340B drug discount program. Supported passage of H.R. 4392. Opposed H.R. 4710, S. 2312 and S.2453 and monitored congressional discussions around the program. Medicare Extenders - Supported extension of Medicare programs that support low-volume and Medicare-dependent hospitals included in H.R.1892. Medicaid Disproportionate Share Hospital (DSH) Payments - Supported delay of implementation of Medicaid DSH payment cuts included in H.R. 1892. Children's Hospital GME Support Reauthorization Act (H.R.5385, S.2597) - Endorsed passage of legislation to reauthorize the Children's Hospital GME program. Supported change to home infusion payments for Part B DME infusion drugs and infusion services payments included in H.R. 1892.

340B Drug Pricing Program - Raised opposition to Medicare reimbursement reductions for hospitals eligible for the 340B drug pricing program. Supported passage of H.R. 4392, H.R 6071. Opposed H.R. 4710, H.R. 6240, S. 2312 and S.2453. Supported Limited Repeal of the IMD Exclusion for substance abuse disorder that was included in H.R. 6, the SUPPORT Communities Act. Children's Hospital GME Support Reauthorization Act (H.R.5385, S.2597) - Endorsed passage of legislation to reauthorize the Children's Hospital GME program.

340B Drug Pricing Program - Highlighted importance of the 340B Drug Pricing program for safety net hospitals and monitored ongoing discussions around reforming the program. Supported passage of H.R. 4392, H.R 6071. Opposed H.R. 4710, H.R. 6240, S. 2312 and S.2453. Group Purchasing - Conducted education and outreach efforts about the value hospital group purchasing organizations deliver the U.S. health care system. Drug Shortages - Advocated for Drug Enforcement Agency to modify total production quotas for injectable opioid solutions to address hospital shortages. Drug Pricing - Supported the CREATES Act (S. 974), The Fair Access to Safe and Timely Generics Act (H.R. 2051), The Preserving Access to Affordable Generics (S.124), The Increasing Competition in Pharmaceuticals Act (S.297) and The Lower Drug Costs through Competition Act (H.R. 749). Opioid Abuse - Supported House passage of H.R. 6 and ongoing efforts to enhance funding and treatment options to address opioid abuse and addiction issues. Overall Hospital Quality Star Ratings - Urged modifications to the methodology used to calculate Overall Hospital Quality Star Ratings Program. Prescription Drug Compounding - Supported ongoing efforts to maintain access to safe and effective drug compounding as the Drug Quality and Safety Act is implemented. Stark Law Reform - Monitored discussions in the House and Senate seeking reforms to the Stark Law. Voiced support for reforms that ease barriers to value-based care arrangements. Medical Device Cybersecurity - Urged additional steps to promote enhanced cybersecurity for networked medical devices.

340B Drug Pricing Program - Opposed changes to eligibility and the structure of the 340B Drug Pricing Program. Supported passage of H.R. 4392, H.R 6071. Opposed H.R. 4710, H.R. 6240, S. 2312 and S.2453. Group Purchasing - Conducted education and outreach efforts about the value hospital group purchasing organizations deliver the U.S. health care system. Drug Shortages - Advocated for Drug Enforcement Agency to modify total production quotas for injectable opioid solutions to address hospital shortages. Drug Pricing - Supported the CREATES Act (S. 974), The Fair Access to Safe and Timely Generics Act (H.R. 2051), The Preserving Access to Affordable Generics (S.124), The Increasing Competition in Pharmaceuticals Act (S.297) and The Lower Drug Costs through Competition Act (H.R. 749). Biosimilar Drug adoption - Supported administrative proposals that would expand the adoption of biosimilar medications. Urged the Food and Drug Administration to finalize guidance related biosimilar interchangeability. Opioid Abuse - Supported passage of H.R. 6 and ongoing efforts to enhance funding and treatment options to address opioid abuse and addiction issues. Supported changes to privacy requirements under 42 CFR Part 2 to better support coordinated care for patients. Overall Hospital Quality Star Ratings - Urged modifications to the methodology used to calculate Overall Hospital Quality Star Ratings Program. Prescription Drug Compounding - Supported ongoing efforts to maintain access to safe and effective drug compounding as the Drug Quality and Safety Act is implemented. Stark Law Reform - Monitored discussions in the House and Senate seeking reforms to the Stark Law. Voiced support for reforms that ease barriers to value-based care arrangements.

340B Drug Pricing Program - Raised opposition to Medicare reimbursement reductions for hospitals eligible for the 340B drug pricing program. Supported passage of H.R. 4392, H.R 6071. Opposed H.R. 4710, H.R. 6240, S. 2312 and S.2453. Supported Limited Repeal of the IMD Exclusion for substance abuse disorder that was included in H.R. 6, the SUPPORT Communities Act. Children's Hospital GME Support Reauthorization Act (H.R.5385, S.2597) - Endorsed passage of legislation to reauthorize the Children's Hospital GME program.

340B Drug Pricing Program - Opposed Medicare reimbursement reductions for hospitals eligible for the 340B drug pricing program. Supported passage of H.R. 4392, H.R 6071. Opposed H.R. 4710, H.R. 6240, S. 2312 and S.2453. Supported partial relaxation of the IMD Exclusion for substance abuse disorder included in H.R. 6, the SUPPORT Communities Act. Children's Hospital GME Support Reauthorization Act (H.R.5385, S.2597) - Endorsed passage of legislation to reauthorize the Children's Hospital GME program. Supported implementation of a competitive acquisition program for prescription drugs under Medicare Part B.

Group Purchasing - Conducted education and outreach efforts about the value hospital group purchasing organizations deliver the U.S. health care system. 340B Drug Pricing Program - Opposed changes to eligibility and the structure of the 340B Drug Pricing Program. Supported passage of H.R. 4392 and H.R 6071. Opposed H.R. 4710, H.R. 6240, S. 2312 and S.2453. Drug Shortages - Engaged in discussions around how ongoing shortages of prescription drugs are impacting hospitals and possible solutions. Advocated for the Drug Enforcement Agency to modify total annual production quotas to address hospital shortage of injectable opioid solutions. Drug Pricing - Supported the CREATES Act (S. 974), The Fair Access to Safe and Timely Generics Act (H.R. 2051), The Preserving Access to Affordable Generics (S.124), The Increasing Competition in Pharmaceuticals Act (S.297) and The Lower Drug Costs through Competition Act (H.R. 749). Biosimilar Drug adoption - Supported administrative proposals that would expand the adoption of biosimilar medications. Urged the Food and Drug Administration to finalize guidance related biosimilar interchangeability. Opioid Abuse - Supported changes to privacy requirements under 42 CFR Part 2 to better support coordinated care for patients. Supported H.R. 6082. Children's Hospital GME Support Reauthorization Act (H.R.5385, S.2597) - Endorsed passage of legislation to reauthorize the Children's Hospital GME program. Overall Hospital Quality Star Ratings - Urged modifications to the methodology used to calculate Overall Hospital Quality Star Ratings Program. Stark Law Reform - Monitored discussions in the House and Senate seeking reforms to the Stark Law. Voiced support for reforms that ease barriers to value-based care arrangements.

340B Drug Pricing Program - Opposed changes to eligibility and the structure of the 340B Drug Pricing Program. Supported passage of H.R. 4392, H.R 6071. Opposed H.R. 4710, H.R. 6240, S. 2312 and S.2453. Group Purchasing - Conducted education and outreach efforts about the value hospital group purchasing organizations deliver the U.S. health care system. Drug Shortages - Advocated for Drug Enforcement Agency to modify total production quotas for injectable opioid solutions to address hospital shortages. Drug Pricing - Supported the CREATES Act (S. 974), The Fair Access to Safe and Timely Generics Act (H.R. 2051), The Preserving Access to Affordable Generics (S.124), The Increasing Competition in Pharmaceuticals Act (S.297) and The Lower Drug Costs through Competition Act (H.R. 749). Biosimilar Drug adoption - Supported administrative proposals that would expand the adoption of biosimilar medications. Urged the Food and Drug Administration to finalize guidance related biosimilar interchangeability. Opioid Abuse - Supported passage of H.R. 6 and ongoing efforts to enhance funding and treatment options to address opioid abuse and addiction issues. Supported changes to privacy requirements under 42 CFR Part 2 to better support coordinated care for patients. Overall Hospital Quality Star Ratings - Urged modifications to the methodology used to calculate Overall Hospital Quality Star Ratings Program. Prescription Drug Compounding - Supported ongoing efforts to maintain access to safe and effective drug compounding as the Drug Quality and Safety Act is implemented. Stark Law Reform - Monitored discussions in the House and Senate seeking reforms to the Stark Law. Voiced support for reforms that ease barriers to value-based care arrangements.

340B Drug Pricing Program - Highlighted importance of the 340B Drug Pricing program for safety net hospitals and monitored ongoing discussions around reforming the program. Supported passage of H.R. 4392, H.R 6071. Opposed H.R. 4710, H.R. 6240, S. 2312 and S.2453. Group Purchasing - Conducted education and outreach efforts about the value hospital group purchasing organizations deliver the U.S. health care system. Drug Shortages - Advocated for Drug Enforcement Agency to modify total production quotas for injectable opioid solutions to address hospital shortages. Drug Pricing - Supported the CREATES Act (S. 974), The Fair Access to Safe and Timely Generics Act (H.R. 2051), The Preserving Access to Affordable Generics (S.124), The Increasing Competition in Pharmaceuticals Act (S.297) and The Lower Drug Costs through Competition Act (H.R. 749). Opioid Abuse - Supported House passage of H.R. 6 and ongoing efforts to enhance funding and treatment options to address opioid abuse and addiction issues. Overall Hospital Quality Star Ratings - Urged modifications to the methodology used to calculate Overall Hospital Quality Star Ratings Program. Prescription Drug Compounding - Supported ongoing efforts to maintain access to safe and effective drug compounding as the Drug Quality and Safety Act is implemented. Stark Law Reform - Monitored discussions in the House and Senate seeking reforms to the Stark Law. Voiced support for reforms that ease barriers to value-based care arrangements. Medical Device Cybersecurity - Urged additional steps to promote enhanced cybersecurity for networked medical devices.

340B Drug Pricing Program - Raised opposition to Medicare reimbursement reductions for hospitals eligible for the 340B drug pricing program. Supported passage of H.R. 4392, H.R 6071. Opposed H.R. 4710, H.R. 6240, S. 2312 and S.2453. Supported Limited Repeal of the IMD Exclusion for substance abuse disorder that was included in H.R. 6, the SUPPORT Communities Act. Children's Hospital GME Support Reauthorization Act (H.R.5385, S.2597) - Endorsed passage of legislation to reauthorize the Children's Hospital GME program.

340B Drug Pricing Program - Opposed Medicare reimbursement reductions for hospitals eligible for the 340B drug pricing program. Supported passage of H.R. 4392, H.R 6071. Opposed H.R. 4710, H.R. 6240, S. 2312 and S.2453. Supported partial relaxation of the IMD Exclusion for substance abuse disorder included in H.R. 6, the SUPPORT Communities Act. Children's Hospital GME Support Reauthorization Act (H.R.5385, S.2597) - Endorsed passage of legislation to reauthorize the Children's Hospital GME program. Supported implementation of a competitive acquisition program for prescription drugs under Medicare Part B.

340B Drug Pricing Program - Opposed Medicare reimbursement reductions for hospitals eligible for the 340B drug pricing program. Supported passage of H.R. 4392, H.R 6071. Opposed H.R. 4710, H.R. 6240, S. 2312 and S.2453. Outpatient Prospective Payment System Site-Neutral Payment Reductions - Opposed implementation of Medicare payment changes that would reduce reimbursement for hospital outpatient facilities.

Group Purchasing - Conducted education and outreach efforts about the value hospital group purchasing organizations deliver the U.S. health care system. 340B Drug Pricing Program - Opposed changes to eligibility and the structure of the 340B Drug Pricing Program. Supported passage of H.R. 4392 and H.R 6071. Opposed H.R. 4710, H.R. 6240, S. 2312 and S.2453. Drug Shortages - Engaged in discussions around how ongoing shortages of prescription drugs are impacting hospitals and possible solutions. Advocated for the Drug Enforcement Agency to modify total annual production quotas to address hospital shortage of injectable opioid solutions. Drug Pricing - Supported the CREATES Act (S. 974), The Fair Access to Safe and Timely Generics Act (H.R. 2051), The Preserving Access to Affordable Generics (S.124), The Increasing Competition in Pharmaceuticals Act (S.297) and The Lower Drug Costs through Competition Act (H.R. 749). Biosimilar Drug adoption - Supported administrative proposals that would expand the adoption of biosimilar medications. Urged the Food and Drug Administration to finalize guidance related biosimilar interchangeability. Opioid Abuse - Supported changes to privacy requirements under 42 CFR Part 2 to better support coordinated care for patients. Supported H.R. 6082. Children's Hospital GME Support Reauthorization Act (H.R.5385, S.2597) - Endorsed passage of legislation to reauthorize the Children's Hospital GME program. Overall Hospital Quality Star Ratings - Urged modifications to the methodology used to calculate Overall Hospital Quality Star Ratings Program. Stark Law Reform - Monitored discussions in the House and Senate seeking reforms to the Stark Law. Voiced support for reforms that ease barriers to value-based care arrangements.

340B Drug Pricing Program - Opposed Medicare reimbursement reductions for hospitals eligible for the 340B drug pricing program. Supported passage of H.R. 4392, H.R 6071. Opposed H.R. 4710, H.R. 6240, S. 2312 and S.2453. Supported partial relaxation of the IMD Exclusion for substance abuse disorder included in H.R. 6, the SUPPORT Communities Act. Children's Hospital GME Support Reauthorization Act (H.R.5385, S.2597) - Endorsed passage of legislation to reauthorize the Children's Hospital GME program. Supported implementation of a competitive acquisition program for prescription drugs under Medicare Part B.

340B Drug Pricing Program - Opposed Medicare reimbursement reductions for hospitals eligible for the 340B drug pricing program. Supported passage of H.R. 4392, H.R 6071. Opposed H.R. 4710, H.R. 6240, S. 2312 and S.2453. Outpatient Prospective Payment System Site-Neutral Payment Reductions - Opposed implementation of Medicare payment changes that would reduce reimbursement for hospital outpatient facilities.

340B Drug Pricing Program - Opposed changes to eligibility and the structure of the 340B Drug Pricing Program. Supported passage of H.R. 4392, H.R 6071. Opposed H.R. 4710, H.R. 6240, S. 2312 and S.2453. Group Purchasing - Conducted education and outreach efforts about the value hospital group purchasing organizations deliver the U.S. health care system. Drug Shortages - Advocated for Drug Enforcement Agency to modify total production quotas for injectable opioid solutions to address hospital shortages. Drug Pricing - Supported the CREATES Act (S. 974), The Fair Access to Safe and Timely Generics Act (H.R. 2051), The Preserving Access to Affordable Generics (S.124), The Increasing Competition in Pharmaceuticals Act (S.297) and The Lower Drug Costs through Competition Act (H.R. 749). Biosimilar Drug adoption - Supported administrative proposals that would expand the adoption of biosimilar medications. Urged the Food and Drug Administration to finalize guidance related biosimilar interchangeability. Opioid Abuse - Supported passage of H.R. 6 and ongoing efforts to enhance funding and treatment options to address opioid abuse and addiction issues. Supported changes to privacy requirements under 42 CFR Part 2 to better support coordinated care for patients. Overall Hospital Quality Star Ratings - Urged modifications to the methodology used to calculate Overall Hospital Quality Star Ratings Program. Prescription Drug Compounding - Supported ongoing efforts to maintain access to safe and effective drug compounding as the Drug Quality and Safety Act is implemented. Stark Law Reform - Monitored discussions in the House and Senate seeking reforms to the Stark Law. Voiced support for reforms that ease barriers to value-based care arrangements.

Group Purchasing - Conducted education and outreach efforts about the value hospital group purchasing organizations deliver the U.S. health care system. 340B Drug Pricing Program - Opposed changes to eligibility and the structure of the 340B Drug Pricing Program. Supported passage of H.R. 4392 and H.R 6071. Opposed H.R. 4710, H.R. 6240, S. 2312 and S.2453. Drug Shortages - Engaged in discussions around how ongoing shortages of prescription drugs are impacting hospitals and possible solutions. Advocated for the Drug Enforcement Agency to modify total annual production quotas to address hospital shortage of injectable opioid solutions. Drug Pricing - Supported the CREATES Act (S. 974), The Fair Access to Safe and Timely Generics Act (H.R. 2051), The Preserving Access to Affordable Generics (S.124), The Increasing Competition in Pharmaceuticals Act (S.297) and The Lower Drug Costs through Competition Act (H.R. 749). Biosimilar Drug adoption - Supported administrative proposals that would expand the adoption of biosimilar medications. Urged the Food and Drug Administration to finalize guidance related biosimilar interchangeability. Opioid Abuse - Supported changes to privacy requirements under 42 CFR Part 2 to better support coordinated care for patients. Supported H.R. 6082. Children's Hospital GME Support Reauthorization Act (H.R.5385, S.2597) - Endorsed passage of legislation to reauthorize the Children's Hospital GME program. Overall Hospital Quality Star Ratings - Urged modifications to the methodology used to calculate Overall Hospital Quality Star Ratings Program. Stark Law Reform - Monitored discussions in the House and Senate seeking reforms to the Stark Law. Voiced support for reforms that ease barriers to value-based care arrangements.

340B Drug Pricing Program - Highlighted importance of the 340B Drug Pricing program for safety net hospitals and monitored ongoing discussions around reforming the program. Supported passage of H.R. 4392, H.R 6071. Opposed H.R. 4710, H.R. 6240, S. 2312 and S.2453. Group Purchasing - Conducted education and outreach efforts about the value hospital group purchasing organizations deliver the U.S. health care system. Drug Shortages - Advocated for Drug Enforcement Agency to modify total production quotas for injectable opioid solutions to address hospital shortages. Drug Pricing - Supported the CREATES Act (S. 974), The Fair Access to Safe and Timely Generics Act (H.R. 2051), The Preserving Access to Affordable Generics (S.124), The Increasing Competition in Pharmaceuticals Act (S.297) and The Lower Drug Costs through Competition Act (H.R. 749). Opioid Abuse - Supported House passage of H.R. 6 and ongoing efforts to enhance funding and treatment options to address opioid abuse and addiction issues. Overall Hospital Quality Star Ratings - Urged modifications to the methodology used to calculate Overall Hospital Quality Star Ratings Program. Prescription Drug Compounding - Supported ongoing efforts to maintain access to safe and effective drug compounding as the Drug Quality and Safety Act is implemented. Stark Law Reform - Monitored discussions in the House and Senate seeking reforms to the Stark Law. Voiced support for reforms that ease barriers to value-based care arrangements. Medical Device Cybersecurity - Urged additional steps to promote enhanced cybersecurity for networked medical devices.

340B Drug Pricing Program - Raised opposition to Medicare reimbursement reductions for hospitals eligible for the 340B drug pricing program. Supported passage of H.R. 4392, H.R 6071. Opposed H.R. 4710, H.R. 6240, S. 2312 and S.2453. Supported Limited Repeal of the IMD Exclusion for substance abuse disorder that was included in H.R. 6, the SUPPORT Communities Act. Children's Hospital GME Support Reauthorization Act (H.R.5385, S.2597) - Endorsed passage of legislation to reauthorize the Children's Hospital GME program.

Group Purchasing - Conducted education and outreach efforts about the value hospital group purchasing organizations deliver the U.S. health care system. Drug Pricing - Supported the CREATES Act (S. 974), The Fair Access to Safe and Timely Generics Act (H.R. 2051), The Preserving Access to Affordable Generics (S.124), The Increasing Competition in Pharmaceuticals Act (S.297) and The Lower Drug Costs through Competition Act (H.R. 749). 340B Drug Discount program - Supported passage of H.R. 4392. Opposed H.R. 4710, S. 2312 and S.2453 and monitored ongoing congressional reports and discussions around the program. Children's Health Insurance Program - Supported passage of legislation to extend the Children's Health Insurance Program. Supported provision in H.R. 195 to extend the program for 6 years, and provisions in H.R. 1892 that continued funding for four additional years. Supported efforts to stabilize ACA insurance markets - including continuing funding for cost-sharing reduction subsidies and other efforts to stabilize insurance markets. Supported inclusion of provision to repeal the Independent Payment Advisory Board (IPAB) in H.R. 1892. Opioid Abuse - Monitored legislation to enhance funding and treatment options to address opioid abuse and addiction issues. Engaged in support of taking steps to ease shortages of hospital-administered intravenous opioid solutions.

340B Drug Pricing Program - Opposed changes to eligibility and the structure of the 340B Drug Pricing Program. Supported passage of H.R. 4392, H.R 6071. Opposed H.R. 4710, H.R. 6240, S. 2312 and S.2453. Group Purchasing - Conducted education and outreach efforts about the value hospital group purchasing organizations deliver the U.S. health care system. Drug Shortages - Advocated for Drug Enforcement Agency to modify total production quotas for injectable opioid solutions to address hospital shortages. Drug Pricing - Supported the CREATES Act (S. 974), The Fair Access to Safe and Timely Generics Act (H.R. 2051), The Preserving Access to Affordable Generics (S.124), The Increasing Competition in Pharmaceuticals Act (S.297) and The Lower Drug Costs through Competition Act (H.R. 749). Biosimilar Drug adoption - Supported administrative proposals that would expand the adoption of biosimilar medications. Urged the Food and Drug Administration to finalize guidance related biosimilar interchangeability. Opioid Abuse - Supported passage of H.R. 6 and ongoing efforts to enhance funding and treatment options to address opioid abuse and addiction issues. Supported changes to privacy requirements under 42 CFR Part 2 to better support coordinated care for patients. Overall Hospital Quality Star Ratings - Urged modifications to the methodology used to calculate Overall Hospital Quality Star Ratings Program. Prescription Drug Compounding - Supported ongoing efforts to maintain access to safe and effective drug compounding as the Drug Quality and Safety Act is implemented. Stark Law Reform - Monitored discussions in the House and Senate seeking reforms to the Stark Law. Voiced support for reforms that ease barriers to value-based care arrangements.

Group Purchasing - Conducted education and outreach efforts about the value hospital group purchasing organizations deliver the U.S. health care system. 340B Drug Pricing Program - Opposed changes to eligibility and the structure of the 340B Drug Pricing Program. Supported passage of H.R. 4392 and H.R 6071. Opposed H.R. 4710, H.R. 6240, S. 2312 and S.2453. Drug Shortages - Engaged in discussions around how ongoing shortages of prescription drugs are impacting hospitals and possible solutions. Advocated for the Drug Enforcement Agency to modify total annual production quotas to address hospital shortage of injectable opioid solutions. Drug Pricing - Supported the CREATES Act (S. 974), The Fair Access to Safe and Timely Generics Act (H.R. 2051), The Preserving Access to Affordable Generics (S.124), The Increasing Competition in Pharmaceuticals Act (S.297) and The Lower Drug Costs through Competition Act (H.R. 749). Biosimilar Drug adoption - Supported administrative proposals that would expand the adoption of biosimilar medications. Urged the Food and Drug Administration to finalize guidance related biosimilar interchangeability. Opioid Abuse - Supported changes to privacy requirements under 42 CFR Part 2 to better support coordinated care for patients. Supported H.R. 6082. Children's Hospital GME Support Reauthorization Act (H.R.5385, S.2597) - Endorsed passage of legislation to reauthorize the Children's Hospital GME program. Overall Hospital Quality Star Ratings - Urged modifications to the methodology used to calculate Overall Hospital Quality Star Ratings Program. Stark Law Reform - Monitored discussions in the House and Senate seeking reforms to the Stark Law. Voiced support for reforms that ease barriers to value-based care arrangements.

340B Drug Pricing Program - Highlighted importance of the 340B Drug Pricing program for safety net hospitals and monitored ongoing discussions around reforming the program. Supported passage of H.R. 4392, H.R 6071. Opposed H.R. 4710, H.R. 6240, S. 2312 and S.2453. Group Purchasing - Conducted education and outreach efforts about the value hospital group purchasing organizations deliver the U.S. health care system. Drug Shortages - Advocated for Drug Enforcement Agency to modify total production quotas for injectable opioid solutions to address hospital shortages. Drug Pricing - Supported the CREATES Act (S. 974), The Fair Access to Safe and Timely Generics Act (H.R. 2051), The Preserving Access to Affordable Generics (S.124), The Increasing Competition in Pharmaceuticals Act (S.297) and The Lower Drug Costs through Competition Act (H.R. 749). Opioid Abuse - Supported House passage of H.R. 6 and ongoing efforts to enhance funding and treatment options to address opioid abuse and addiction issues. Overall Hospital Quality Star Ratings - Urged modifications to the methodology used to calculate Overall Hospital Quality Star Ratings Program. Prescription Drug Compounding - Supported ongoing efforts to maintain access to safe and effective drug compounding as the Drug Quality and Safety Act is implemented. Stark Law Reform - Monitored discussions in the House and Senate seeking reforms to the Stark Law. Voiced support for reforms that ease barriers to value-based care arrangements. Medical Device Cybersecurity - Urged additional steps to promote enhanced cybersecurity for networked medical devices.

340B Drug Pricing Program - Highlighted importance of the 340B Drug Pricing program for safety net hospitals and monitored ongoing discussions around reforming the program. Supported passage of H.R. 4392, H.R 6071. Opposed H.R. 4710, H.R. 6240, S. 2312 and S.2453. Group Purchasing - Conducted education and outreach efforts about the value hospital group purchasing organizations deliver the U.S. health care system. Drug Shortages - Advocated for Drug Enforcement Agency to modify total production quotas for injectable opioid solutions to address hospital shortages. Drug Pricing - Supported the CREATES Act (S. 974), The Fair Access to Safe and Timely Generics Act (H.R. 2051), The Preserving Access to Affordable Generics (S.124), The Increasing Competition in Pharmaceuticals Act (S.297) and The Lower Drug Costs through Competition Act (H.R. 749). Opioid Abuse - Supported House passage of H.R. 6 and ongoing efforts to enhance funding and treatment options to address opioid abuse and addiction issues. Overall Hospital Quality Star Ratings - Urged modifications to the methodology used to calculate Overall Hospital Quality Star Ratings Program. Prescription Drug Compounding - Supported ongoing efforts to maintain access to safe and effective drug compounding as the Drug Quality and Safety Act is implemented. Stark Law Reform - Monitored discussions in the House and Senate seeking reforms to the Stark Law. Voiced support for reforms that ease barriers to value-based care arrangements. Medical Device Cybersecurity - Urged additional steps to promote enhanced cybersecurity for networked medical devices.

Group Purchasing - Conducted education and outreach efforts about the value hospital group purchasing organizations deliver the U.S. health care system. 340B Drug Pricing Program - Opposed changes to eligibility and the structure of the 340B Drug Pricing Program. Supported passage of H.R. 4392 and H.R 6071. Opposed H.R. 4710, H.R. 6240, S. 2312 and S.2453. Drug Shortages - Engaged in discussions around how ongoing shortages of prescription drugs are impacting hospitals and possible solutions. Advocated for the Drug Enforcement Agency to modify total annual production quotas to address hospital shortage of injectable opioid solutions. Drug Pricing - Supported the CREATES Act (S. 974), The Fair Access to Safe and Timely Generics Act (H.R. 2051), The Preserving Access to Affordable Generics (S.124), The Increasing Competition in Pharmaceuticals Act (S.297) and The Lower Drug Costs through Competition Act (H.R. 749). Biosimilar Drug adoption - Supported administrative proposals that would expand the adoption of biosimilar medications. Urged the Food and Drug Administration to finalize guidance related biosimilar interchangeability. Opioid Abuse - Supported changes to privacy requirements under 42 CFR Part 2 to better support coordinated care for patients. Supported H.R. 6082. Children's Hospital GME Support Reauthorization Act (H.R.5385, S.2597) - Endorsed passage of legislation to reauthorize the Children's Hospital GME program. Overall Hospital Quality Star Ratings - Urged modifications to the methodology used to calculate Overall Hospital Quality Star Ratings Program. Stark Law Reform - Monitored discussions in the House and Senate seeking reforms to the Stark Law. Voiced support for reforms that ease barriers to value-based care arrangements.

340B Drug Pricing Program - Opposed changes to eligibility and the structure of the 340B Drug Pricing Program. Supported passage of H.R. 4392, H.R 6071. Opposed H.R. 4710, H.R. 6240, S. 2312 and S.2453. Group Purchasing - Conducted education and outreach efforts about the value hospital group purchasing organizations deliver the U.S. health care system. Drug Shortages - Advocated for Drug Enforcement Agency to modify total production quotas for injectable opioid solutions to address hospital shortages. Drug Pricing - Supported the CREATES Act (S. 974), The Fair Access to Safe and Timely Generics Act (H.R. 2051), The Preserving Access to Affordable Generics (S.124), The Increasing Competition in Pharmaceuticals Act (S.297) and The Lower Drug Costs through Competition Act (H.R. 749). Biosimilar Drug adoption - Supported administrative proposals that would expand the adoption of biosimilar medications. Urged the Food and Drug Administration to finalize guidance related biosimilar interchangeability. Opioid Abuse - Supported passage of H.R. 6 and ongoing efforts to enhance funding and treatment options to address opioid abuse and addiction issues. Supported changes to privacy requirements under 42 CFR Part 2 to better support coordinated care for patients. Overall Hospital Quality Star Ratings - Urged modifications to the methodology used to calculate Overall Hospital Quality Star Ratings Program. Prescription Drug Compounding - Supported ongoing efforts to maintain access to safe and effective drug compounding as the Drug Quality and Safety Act is implemented. Stark Law Reform - Monitored discussions in the House and Senate seeking reforms to the Stark Law. Voiced support for reforms that ease barriers to value-based care arrangements.

Group Purchasing - Conducted education and outreach efforts about the value hospital group purchasing organizations deliver the U.S. health care system. Drug Pricing - Supported the CREATES Act (S. 974), The Fair Access to Safe and Timely Generics Act (H.R. 2051), The Preserving Access to Affordable Generics (S.124), The Increasing Competition in Pharmaceuticals Act (S.297) and The Lower Drug Costs through Competition Act (H.R. 749). 340B Drug Discount program - Supported passage of H.R. 4392. Opposed H.R. 4710, S. 2312 and S.2453 and monitored ongoing congressional reports and discussions around the program. Children's Health Insurance Program - Supported passage of legislation to extend the Children's Health Insurance Program. Supported provision in H.R. 195 to extend the program for 6 years, and provisions in H.R. 1892 that continued funding for four additional years. Supported efforts to stabilize ACA insurance markets - including continuing funding for cost-sharing reduction subsidies and other efforts to stabilize insurance markets. Supported inclusion of provision to repeal the Independent Payment Advisory Board (IPAB) in H.R. 1892. Opioid Abuse - Monitored legislation to enhance funding and treatment options to address opioid abuse and addiction issues. Engaged in support of taking steps to ease shortages of hospital-administered intravenous opioid solutions.

340B Drug Pricing Program - Raised opposition to Medicare reimbursement reductions for hospitals eligible for the 340B drug pricing program. Supported passage of H.R. 4392, H.R 6071. Opposed H.R. 4710, H.R. 6240, S. 2312 and S.2453. Supported Limited Repeal of the IMD Exclusion for substance abuse disorder that was included in H.R. 6, the SUPPORT Communities Act. Children's Hospital GME Support Reauthorization Act (H.R.5385, S.2597) - Endorsed passage of legislation to reauthorize the Children's Hospital GME program.

340B Drug Pricing Program - Opposed Medicare reimbursement reductions for hospitals eligible for the 340B drug pricing program. Supported passage of H.R. 4392, H.R 6071. Opposed H.R. 4710, H.R. 6240, S. 2312 and S.2453. Supported partial relaxation of the IMD Exclusion for substance abuse disorder included in H.R. 6, the SUPPORT Communities Act. Children's Hospital GME Support Reauthorization Act (H.R.5385, S.2597) - Endorsed passage of legislation to reauthorize the Children's Hospital GME program. Supported implementation of a competitive acquisition program for prescription drugs under Medicare Part B.

340B Drug Pricing Program - Opposed Medicare reimbursement reductions for hospitals eligible for the 340B drug pricing program. Supported passage of H.R. 4392, H.R 6071. Opposed H.R. 4710, H.R. 6240, S. 2312 and S.2453. Outpatient Prospective Payment System Site-Neutral Payment Reductions - Opposed implementation of Medicare payment changes that would reduce reimbursement for hospital outpatient facilities.

Group Purchasing - Conducted education and outreach efforts about the value hospital group purchasing organizations deliver the U.S. health care system. 340B Drug Pricing Program - Opposed changes to eligibility and the structure of the 340B Drug Pricing Program. Supported passage of H.R. 4392 and H.R 6071. Opposed H.R. 4710, H.R. 6240, S. 2312 and S.2453. Drug Shortages - Engaged in discussions around how ongoing shortages of prescription drugs are impacting hospitals and possible solutions. Advocated for the Drug Enforcement Agency to modify total annual production quotas to address hospital shortage of injectable opioid solutions. Drug Pricing - Supported the CREATES Act (S. 974), The Fair Access to Safe and Timely Generics Act (H.R. 2051), The Preserving Access to Affordable Generics (S.124), The Increasing Competition in Pharmaceuticals Act (S.297) and The Lower Drug Costs through Competition Act (H.R. 749). Biosimilar Drug adoption - Supported administrative proposals that would expand the adoption of biosimilar medications. Urged the Food and Drug Administration to finalize guidance related biosimilar interchangeability. Opioid Abuse - Supported changes to privacy requirements under 42 CFR Part 2 to better support coordinated care for patients. Supported H.R. 6082. Children's Hospital GME Support Reauthorization Act (H.R.5385, S.2597) - Endorsed passage of legislation to reauthorize the Children's Hospital GME program. Overall Hospital Quality Star Ratings - Urged modifications to the methodology used to calculate Overall Hospital Quality Star Ratings Program. Stark Law Reform - Monitored discussions in the House and Senate seeking reforms to the Stark Law. Voiced support for reforms that ease barriers to value-based care arrangements.

340B Drug Pricing Program - Opposed changes to eligibility and the structure of the 340B Drug Pricing Program. Supported passage of H.R. 4392, H.R 6071. Opposed H.R. 4710, H.R. 6240, S. 2312 and S.2453. Group Purchasing - Conducted education and outreach efforts about the value hospital group purchasing organizations deliver the U.S. health care system. Drug Shortages - Advocated for Drug Enforcement Agency to modify total production quotas for injectable opioid solutions to address hospital shortages. Drug Pricing - Supported the CREATES Act (S. 974), The Fair Access to Safe and Timely Generics Act (H.R. 2051), The Preserving Access to Affordable Generics (S.124), The Increasing Competition in Pharmaceuticals Act (S.297) and The Lower Drug Costs through Competition Act (H.R. 749). Biosimilar Drug adoption - Supported administrative proposals that would expand the adoption of biosimilar medications. Urged the Food and Drug Administration to finalize guidance related biosimilar interchangeability. Opioid Abuse - Supported passage of H.R. 6 and ongoing efforts to enhance funding and treatment options to address opioid abuse and addiction issues. Supported changes to privacy requirements under 42 CFR Part 2 to better support coordinated care for patients. Overall Hospital Quality Star Ratings - Urged modifications to the methodology used to calculate Overall Hospital Quality Star Ratings Program. Prescription Drug Compounding - Supported ongoing efforts to maintain access to safe and effective drug compounding as the Drug Quality and Safety Act is implemented. Stark Law Reform - Monitored discussions in the House and Senate seeking reforms to the Stark Law. Voiced support for reforms that ease barriers to value-based care arrangements.

Group Purchasing - Conducted education and outreach efforts about the value hospital group purchasing organizations deliver the U.S. health care system. Drug Pricing - Supported the CREATES Act (S. 974), The Fair Access to Safe and Timely Generics Act (H.R. 2051), The Preserving Access to Affordable Generics (S.124), The Increasing Competition in Pharmaceuticals Act (S.297) and The Lower Drug Costs through Competition Act (H.R. 749). 340B Drug Discount program - Supported passage of H.R. 4392. Opposed H.R. 4710, S. 2312 and S.2453 and monitored ongoing congressional reports and discussions around the program. Children's Health Insurance Program - Supported passage of legislation to extend the Children's Health Insurance Program. Supported provision in H.R. 195 to extend the program for 6 years, and provisions in H.R. 1892 that continued funding for four additional years. Supported efforts to stabilize ACA insurance markets - including continuing funding for cost-sharing reduction subsidies and other efforts to stabilize insurance markets. Supported inclusion of provision to repeal the Independent Payment Advisory Board (IPAB) in H.R. 1892. Opioid Abuse - Monitored legislation to enhance funding and treatment options to address opioid abuse and addiction issues. Engaged in support of taking steps to ease shortages of hospital-administered intravenous opioid solutions.

340B Drug Pricing Program - Highlighted importance of the 340B Drug Pricing program for safety net hospitals and monitored ongoing discussions around reforming the program. Supported passage of H.R. 4392, H.R 6071. Opposed H.R. 4710, H.R. 6240, S. 2312 and S.2453. Group Purchasing - Conducted education and outreach efforts about the value hospital group purchasing organizations deliver the U.S. health care system. Drug Shortages - Advocated for Drug Enforcement Agency to modify total production quotas for injectable opioid solutions to address hospital shortages. Drug Pricing - Supported the CREATES Act (S. 974), The Fair Access to Safe and Timely Generics Act (H.R. 2051), The Preserving Access to Affordable Generics (S.124), The Increasing Competition in Pharmaceuticals Act (S.297) and The Lower Drug Costs through Competition Act (H.R. 749). Opioid Abuse - Supported House passage of H.R. 6 and ongoing efforts to enhance funding and treatment options to address opioid abuse and addiction issues. Overall Hospital Quality Star Ratings - Urged modifications to the methodology used to calculate Overall Hospital Quality Star Ratings Program. Prescription Drug Compounding - Supported ongoing efforts to maintain access to safe and effective drug compounding as the Drug Quality and Safety Act is implemented. Stark Law Reform - Monitored discussions in the House and Senate seeking reforms to the Stark Law. Voiced support for reforms that ease barriers to value-based care arrangements. Medical Device Cybersecurity - Urged additional steps to promote enhanced cybersecurity for networked medical devices.

340B Drug Discount Program - Opposed Medicare reimbursement reductions for hospitals eligible for the 340B drug discount program. Supported passage of H.R. 4392. Opposed H.R. 4710, S. 2312 and S.2453 and monitored congressional discussions around the program. Medicare Extenders - Supported extension of Medicare programs that support low-volume and Medicare-dependent hospitals included in H.R.1892. Medicaid Disproportionate Share Hospital (DSH) Payments - Supported delay of implementation of Medicaid DSH payment cuts included in H.R. 1892. Children's Hospital GME Support Reauthorization Act (H.R.5385, S.2597) - Endorsed passage of legislation to reauthorize the Children's Hospital GME program. Supported change to home infusion payments for Part B DME infusion drugs and infusion services payments included in H.R. 1892.

340B Drug Discount Program - Opposed Medicare reimbursement reductions for hospitals eligible for the 340B drug discount program. Supported passage of H.R. 4392. Opposed H.R. 4710, S. 2312 and S.2453 and monitored congressional discussions around the program. Medicare Extenders - Supported extension of Medicare programs that support low-volume and Medicare-dependent hospitals included in H.R.1892. Medicaid Disproportionate Share Hospital (DSH) Payments - Supported delay of implementation of Medicaid DSH payment cuts included in H.R. 1892. Children's Hospital GME Support Reauthorization Act (H.R.5385, S.2597) - Endorsed passage of legislation to reauthorize the Children's Hospital GME program. Supported change to home infusion payments for Part B DME infusion drugs and infusion services payments included in H.R. 1892.

340B Drug Pricing Program - Highlighted importance of the 340B Drug Pricing program for safety net hospitals and monitored ongoing discussions around reforming the program. Supported passage of H.R. 4392, H.R 6071. Opposed H.R. 4710, H.R. 6240, S. 2312 and S.2453. Group Purchasing - Conducted education and outreach efforts about the value hospital group purchasing organizations deliver the U.S. health care system. Drug Shortages - Advocated for Drug Enforcement Agency to modify total production quotas for injectable opioid solutions to address hospital shortages. Drug Pricing - Supported the CREATES Act (S. 974), The Fair Access to Safe and Timely Generics Act (H.R. 2051), The Preserving Access to Affordable Generics (S.124), The Increasing Competition in Pharmaceuticals Act (S.297) and The Lower Drug Costs through Competition Act (H.R. 749). Opioid Abuse - Supported House passage of H.R. 6 and ongoing efforts to enhance funding and treatment options to address opioid abuse and addiction issues. Overall Hospital Quality Star Ratings - Urged modifications to the methodology used to calculate Overall Hospital Quality Star Ratings Program. Prescription Drug Compounding - Supported ongoing efforts to maintain access to safe and effective drug compounding as the Drug Quality and Safety Act is implemented. Stark Law Reform - Monitored discussions in the House and Senate seeking reforms to the Stark Law. Voiced support for reforms that ease barriers to value-based care arrangements. Medical Device Cybersecurity - Urged additional steps to promote enhanced cybersecurity for networked medical devices.

340B Drug Pricing Program - Opposed Medicare reimbursement reductions for hospitals eligible for the 340B drug pricing program. Supported passage of H.R. 4392, H.R 6071. Opposed H.R. 4710, H.R. 6240, S. 2312 and S.2453. Outpatient Prospective Payment System Site-Neutral Payment Reductions - Opposed implementation of Medicare payment changes that would reduce reimbursement for hospital outpatient facilities.

Group Purchasing - Conducted education and outreach efforts about the value hospital group purchasing organizations deliver the U.S. health care system. Drug Pricing - Supported the CREATES Act (S. 974), The Fair Access to Safe and Timely Generics Act (H.R. 2051), The Preserving Access to Affordable Generics (S.124), The Increasing Competition in Pharmaceuticals Act (S.297) and The Lower Drug Costs through Competition Act (H.R. 749). 340B Drug Discount program - Supported passage of H.R. 4392. Opposed H.R. 4710, S. 2312 and S.2453 and monitored ongoing congressional reports and discussions around the program. Children's Health Insurance Program - Supported passage of legislation to extend the Children's Health Insurance Program. Supported provision in H.R. 195 to extend the program for 6 years, and provisions in H.R. 1892 that continued funding for four additional years. Supported efforts to stabilize ACA insurance markets - including continuing funding for cost-sharing reduction subsidies and other efforts to stabilize insurance markets. Supported inclusion of provision to repeal the Independent Payment Advisory Board (IPAB) in H.R. 1892. Opioid Abuse - Monitored legislation to enhance funding and treatment options to address opioid abuse and addiction issues. Engaged in support of taking steps to ease shortages of hospital-administered intravenous opioid solutions.

340B Drug Pricing Program - Opposed changes to eligibility and the structure of the 340B Drug Pricing Program. Supported passage of H.R. 4392, H.R 6071. Opposed H.R. 4710, H.R. 6240, S. 2312 and S.2453. Group Purchasing - Conducted education and outreach efforts about the value hospital group purchasing organizations deliver the U.S. health care system. Drug Shortages - Advocated for Drug Enforcement Agency to modify total production quotas for injectable opioid solutions to address hospital shortages. Drug Pricing - Supported the CREATES Act (S. 974), The Fair Access to Safe and Timely Generics Act (H.R. 2051), The Preserving Access to Affordable Generics (S.124), The Increasing Competition in Pharmaceuticals Act (S.297) and The Lower Drug Costs through Competition Act (H.R. 749). Biosimilar Drug adoption - Supported administrative proposals that would expand the adoption of biosimilar medications. Urged the Food and Drug Administration to finalize guidance related biosimilar interchangeability. Opioid Abuse - Supported passage of H.R. 6 and ongoing efforts to enhance funding and treatment options to address opioid abuse and addiction issues. Supported changes to privacy requirements under 42 CFR Part 2 to better support coordinated care for patients. Overall Hospital Quality Star Ratings - Urged modifications to the methodology used to calculate Overall Hospital Quality Star Ratings Program. Prescription Drug Compounding - Supported ongoing efforts to maintain access to safe and effective drug compounding as the Drug Quality and Safety Act is implemented. Stark Law Reform - Monitored discussions in the House and Senate seeking reforms to the Stark Law. Voiced support for reforms that ease barriers to value-based care arrangements.

Group Purchasing - Conducted education and outreach efforts about the value hospital group purchasing organizations deliver the U.S. health care system. 340B Drug Pricing Program - Opposed changes to eligibility and the structure of the 340B Drug Pricing Program. Supported passage of H.R. 4392 and H.R 6071. Opposed H.R. 4710, H.R. 6240, S. 2312 and S.2453. Drug Shortages - Engaged in discussions around how ongoing shortages of prescription drugs are impacting hospitals and possible solutions. Advocated for the Drug Enforcement Agency to modify total annual production quotas to address hospital shortage of injectable opioid solutions. Drug Pricing - Supported the CREATES Act (S. 974), The Fair Access to Safe and Timely Generics Act (H.R. 2051), The Preserving Access to Affordable Generics (S.124), The Increasing Competition in Pharmaceuticals Act (S.297) and The Lower Drug Costs through Competition Act (H.R. 749). Biosimilar Drug adoption - Supported administrative proposals that would expand the adoption of biosimilar medications. Urged the Food and Drug Administration to finalize guidance related biosimilar interchangeability. Opioid Abuse - Supported changes to privacy requirements under 42 CFR Part 2 to better support coordinated care for patients. Supported H.R. 6082. Children's Hospital GME Support Reauthorization Act (H.R.5385, S.2597) - Endorsed passage of legislation to reauthorize the Children's Hospital GME program. Overall Hospital Quality Star Ratings - Urged modifications to the methodology used to calculate Overall Hospital Quality Star Ratings Program. Stark Law Reform - Monitored discussions in the House and Senate seeking reforms to the Stark Law. Voiced support for reforms that ease barriers to value-based care arrangements.

340B Drug Pricing Program - Opposed Medicare reimbursement reductions for hospitals eligible for the 340B drug pricing program. Supported passage of H.R. 4392, H.R 6071. Opposed H.R. 4710, H.R. 6240, S. 2312 and S.2453. Supported partial relaxation of the IMD Exclusion for substance abuse disorder included in H.R. 6, the SUPPORT Communities Act. Children's Hospital GME Support Reauthorization Act (H.R.5385, S.2597) - Endorsed passage of legislation to reauthorize the Children's Hospital GME program. Supported implementation of a competitive acquisition program for prescription drugs under Medicare Part B.

340B Drug Pricing Program - Raised opposition to Medicare reimbursement reductions for hospitals eligible for the 340B drug pricing program. Supported passage of H.R. 4392, H.R 6071. Opposed H.R. 4710, H.R. 6240, S. 2312 and S.2453. Supported Limited Repeal of the IMD Exclusion for substance abuse disorder that was included in H.R. 6, the SUPPORT Communities Act. Children's Hospital GME Support Reauthorization Act (H.R.5385, S.2597) - Endorsed passage of legislation to reauthorize the Children's Hospital GME program.

340B Drug Discount Program - Opposed Medicare reimbursement reductions for hospitals eligible for the 340B drug discount program. Supported passage of H.R. 4392. Opposed H.R. 4710, S. 2312 and S.2453 and monitored congressional discussions around the program. Medicare Extenders - Supported extension of Medicare programs that support low-volume and Medicare-dependent hospitals included in H.R.1892. Medicaid Disproportionate Share Hospital (DSH) Payments - Supported delay of implementation of Medicaid DSH payment cuts included in H.R. 1892. Children's Hospital GME Support Reauthorization Act (H.R.5385, S.2597) - Endorsed passage of legislation to reauthorize the Children's Hospital GME program. Supported change to home infusion payments for Part B DME infusion drugs and infusion services payments included in H.R. 1892.

340B Drug Pricing Program - Raised opposition to Medicare reimbursement reductions for hospitals eligible for the 340B drug pricing program. Supported passage of H.R. 4392, H.R 6071. Opposed H.R. 4710, H.R. 6240, S. 2312 and S.2453. Supported Limited Repeal of the IMD Exclusion for substance abuse disorder that was included in H.R. 6, the SUPPORT Communities Act. Children's Hospital GME Support Reauthorization Act (H.R.5385, S.2597) - Endorsed passage of legislation to reauthorize the Children's Hospital GME program.

340B Drug Pricing Program - Opposed Medicare reimbursement reductions for hospitals eligible for the 340B drug pricing program. Supported passage of H.R. 4392, H.R 6071. Opposed H.R. 4710, H.R. 6240, S. 2312 and S.2453. Supported partial relaxation of the IMD Exclusion for substance abuse disorder included in H.R. 6, the SUPPORT Communities Act. Children's Hospital GME Support Reauthorization Act (H.R.5385, S.2597) - Endorsed passage of legislation to reauthorize the Children's Hospital GME program. Supported implementation of a competitive acquisition program for prescription drugs under Medicare Part B.

Group Purchasing - Conducted education and outreach efforts about the value hospital group purchasing organizations deliver the U.S. health care system. 340B Drug Pricing Program - Opposed changes to eligibility and the structure of the 340B Drug Pricing Program. Supported passage of H.R. 4392 and H.R 6071. Opposed H.R. 4710, H.R. 6240, S. 2312 and S.2453. Drug Shortages - Engaged in discussions around how ongoing shortages of prescription drugs are impacting hospitals and possible solutions. Advocated for the Drug Enforcement Agency to modify total annual production quotas to address hospital shortage of injectable opioid solutions. Drug Pricing - Supported the CREATES Act (S. 974), The Fair Access to Safe and Timely Generics Act (H.R. 2051), The Preserving Access to Affordable Generics (S.124), The Increasing Competition in Pharmaceuticals Act (S.297) and The Lower Drug Costs through Competition Act (H.R. 749). Biosimilar Drug adoption - Supported administrative proposals that would expand the adoption of biosimilar medications. Urged the Food and Drug Administration to finalize guidance related biosimilar interchangeability. Opioid Abuse - Supported changes to privacy requirements under 42 CFR Part 2 to better support coordinated care for patients. Supported H.R. 6082. Children's Hospital GME Support Reauthorization Act (H.R.5385, S.2597) - Endorsed passage of legislation to reauthorize the Children's Hospital GME program. Overall Hospital Quality Star Ratings - Urged modifications to the methodology used to calculate Overall Hospital Quality Star Ratings Program. Stark Law Reform - Monitored discussions in the House and Senate seeking reforms to the Stark Law. Voiced support for reforms that ease barriers to value-based care arrangements.